Canada - Engels - Health Canada

sandoz canada incorporated - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - Engels - Health Canada

sandoz canada incorporated - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Verenigde Staten - Engels - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 0.1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

Verenigde Staten - Engels - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

Canada - Engels - Health Canada

omega laboratories limited - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - Engels - Health Canada

strides pharma canada inc - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Canada - Engels - Health Canada

jamp pharma corporation - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml - concentrate for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - adults: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy. the prevention of nausea and vomiting induced by radiotherapy. the prevention and treatment of postoperative nausea and vomiting. children: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Verenigde Staten - Engels - NLM (National Library of Medicine)

wockhardt usa llc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy  category  b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predi

Canada - Engels - Health Canada

apotex inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists